Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 13-17, 2024, in Barcelona, Spain. The presentations will highlight advancements in solid tumor oncology research, featuring data from trials of zanidatamab and Zepzelca® (lurbinectedin).
The congress will showcase new and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody. This trial examines zanidatamab in combination with chemotherapy for the first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA). The presentation will include findings on overall survival and longer follow-up data. Additionally, a mini-oral presentation will feature data from a Phase 2 study of zanidatamab combined with chemotherapy and bevacizumab for first-line treatment of HER2-positive metastatic colorectal cancer, demonstrating promising antitumor activity.
Rob Iannone, M.D., M.S.C.E., Executive Vice President, Global Head of Research and Development, and Chief Medical Officer of Jazz Pharmaceuticals, expressed enthusiasm about presenting these new insights: “We look forward to sharing more mature data from our oncology solid tumor clinical development program at this year’s ESMO congress, particularly for zanidatamab in HER2-positive metastatic gastroesophageal adenocarcinoma. We are excited about advancing our clinical development program, including the upcoming Phase 3 trial expected to report in Q2 2025, which could support global regulatory submissions.”
In addition to zanidatamab data, findings on Zepzelca will also be presented. This includes results from a Phase 2 trial evaluating the safety and efficacy of lurbinectedin combined with irinotecan in relapsed small cell lung cancer (SCLC) patients, including those with a Chemotherapy-Free Interval (CTFI) of 30-90 days—a group with generally poor prognosis. These results reinforce the rationale for this combination in the ongoing LAGOON confirmatory trial.
